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ABSTRACT
An analysis of the main advantages and shortcomings of the existing inactivated and live vaccines against the equine influenza 
viruses (EIVs) is given in this paper. For the first time, the most important information, concerning the development of a new live 
modified cold-adapted (ca) equine influenza virus vaccine based on the A/HK/Otar/6:2/2010 strain is summarized. We discuss 
a number of unique features of the developed vaccine that have not previously been reported, and compare the new vaccine 
with the existing equine influenza vaccines. The properties of the developed equine vaccine include: long-lasting (12 months or 
more) protective immunity after a single immunization; sterile immunity after double vaccination; cross-protection against the 
heterologous virus at 12 months after double vaccination and the differentiation of infected from vaccinated animals.
The equine influenza is an acute contagious virus disease 
characterized by the development of the catarrhal 
inflammation of the respiratory tract, general depression, 
short-term fever, and dry sickly cough and in the severe 
cases – by the development of pneumonia. Among the 
known equine influenza virus (EIV) subtypes H7N7 
and H3N8, the latter is considered the most prevalent. 
These viruses pose a significant threat to equine health 
as well as economic problems for horse breeding [1]. At 
present, the most efficient way to protect horses from 
influenza is a complex of specific preventive measures, 
which are accomplished with the use of inactivated and 
live vaccines.
Starting from 1960s, inactivated vaccines, containing 
the whole virus particles or their subunits, were 
developed and widely used in veterinary practice. The 
lack of virus replication, which ensures the vaccine 
safety, is the main advantage of this vaccine type [2]. At 
the same time, the main disadvantages of inactivated 
vaccines are weak immunogenicity caused by the 
formation of an exclusively humoral immune response 
as well as short-term immunity, which requires multiple 
immunizations [3, 4, 5]. For example, since the antiviral 
antibodies IgG(T), which are formed in the course of 
immunization with the inactivated vaccines, are short-
lived (not more than 100 days after vaccination), triple 
immunization (first two with a 4 to 6 week interval 
and the third on the 5th or 6th month) is needed for the 
formation of the 12 month humoral immunity in horses 
[3, 4, 5]. This immunization scheme is critical because, 
between the second and third vaccination, horses in field 
conditions are the most vulnerable to influenza virus 
infection [7]. In addition, immunization with some of the 
inactivated vaccines containing adjuvants (phosphate or 
hydroxide of aluminum) leads to undesirable effects such 
as an inflammatory reaction and pain at the injection 
site of the intramuscularly vaccinated animals [8]. This 
reaction is also related to the use of chicken embryos 
for the vaccine production: even after the purification, 
the vaccine still contains significant amounts of egg 
proteins, which can cause undesirable reactions in the 
case of multiple intramuscular injections [2]. 
On the other hand, live attenuated vaccines unlike 
inactivated vaccines show the most promising results 
in terms of protection efficacy in horses. Among the 
live attenuated vaccines, the preparations produced on 
the basis of the cold adapted (ca) virus strains play an 
exceptional role. The live vaccine virus has the ability 
to replicate in the upper but not in the lower airways, 
where the temperature is elevated, unlike the wild virus, 
which replicates in the lower airways, that usually leads 
to inflammation like bronchitis and pneumonia [9]. The 
vaccinated horses have the light form of an influenza 
infection, which leads to the formation of antiviral 
humoral and cell immune responses. Moreover, the ca 
vaccine, unlike the inactivated vaccines, is capable of 
causing cross-reactive T-cell immunity in the vaccinated 
animals, which is quite important considering the high 
influenza virus antigenic variability (antigenic drift) 
[10]. The first live vaccine from the ca virus strain 
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against equine influenza was developed and successfully 
implemented in the USA. The live ca vaccine (Flu Avert® I.N., 
Heska Corporation), which is administered intranasally, is 
licensed and has been widely used in the USA since 1999 
[11]. It contains the North American ca strain A/equine/
Kentucky/1991 (H3N8), but at the same time it can protect 
from the viruses of H3N8 subtype of European lineage. 
In spite of the fact that the Flu Avert® vaccine does not 
induce a high level of the humoral antibodies, the single 
immunization with this vaccine provides longer lasting 
protection (at least 6 months) than inactivated vaccines. 
Moreover, animals inoculated with this vaccine develop 
secretory IgA antibodies that are able to neutralize the 
virus at early stage of the infectious process in the upper 
airways [9]. Despite all of the advantages, there are 
some concerns about the safety of ca vaccines. The main 
concern is related to the risk of the possible reversion 
of the vaccine virus or the generation of the reassortant 
with the circulating in the equine body wild type virus, 
resulting in the formation of new pathogenic viruses [2]. 
Though these apprehensions are justified, this possibility 
can be excluded based on more than 20 years of positive 
experience using live intranasal attenuated influenza 
vaccine in people in Russia, and recently in North America 
and Western Europe (FluMist®) [2]. In the case of the ca 
EIV vaccine, it has been proven experimentally that the 
ca strains retain the temperature sensitive (ts) phenotype 
in vivo in the course of five consecutive passages from 
one horse to another, and suppress the replication of 
the wild type virus in the equine upper respiratory tract 
[10]. Therefore, the risk of reversion or reassortment is 
minimal, and the ca vaccine against EIV could be used as 
the therapy for an equine influenza infection [11, 12].
One more prophylactic preparation that has a practical 
application (licensed in the EU in 2003) is a live vaccine 
based on canarypox recombinant virus (ProtegFlu, Merial 
Ltd., UK) [2]. This vaccine includes two canarypox virus 
vectors coding the hemagglutinins (HA) of EIV strains 
A/equine/Newmarket/2/93 (H3N8) (European lineage) 
and A/equine/Kentucky/94 (H3N8) (American lineage). 
Unlike the inactivated vaccines, this vaccine is able to 
induce a humoral response, including the secretory IgA 
antibodies as well as the cellular immune response in 
the vaccinated animals [13, 14]. However, as in the case 
of inactivated vaccines, the triple immunization with 
this vaccine (first two – with 35 days interval, and the 
third – in the course of the 6th month) is necessary for 
the formation of 12 months long protective immune 
response in horses [15]. Furthermore, since this vaccine 
contains the adjuvant Carbomer 974P, it quite often 
causes local undesirable reactions in vaccinated horses 
[16, 17]. The most important feature of this vaccine 
type is the formation of immunity to the corresponding 
virus vector in immunized animals already after the 
first immunization. The immunity developed after the 
second administration of the same virus vector prevents 
the reproduction of these viruses and, consequently, 
the expression of foreign proteins [2, 17, 18]. In order to 
overcome this problem, Breathnach et al. successfully 
applied the method of cross-immunization [19]. This 
method involves the vaccination first by the DNA 
vaccine that codes the HA and the nucleoprotein (NP) of 
A/equine/Kentucky/1/81 (H3N8) strain, and subsequent 
vaccinations (on the 6th and 10th week) – by the modified 
vaccinia virus Ankara that codes the same proteins. 
However, this scheme did not find practical application 
due to its complexity and low productivity.
Thus, if we exclude the vaccines that are still in the 
development stages (DNA vaccines [20, 21] and live 
attenuated influenza virus vaccines produced by reverse 
genetics [22, 23]), only inactivated, live ca, and vector 
vaccines have broad practical application against the 
equine influenza at present. Therefore, when developing 
a safe and effective vaccine against H3N8 EIV, which in 
2007 caused a large influenza outbreak in Kazakhstan 
(around 200,000 horses fell ill with a lethal outcome 
in 50,000 cases including 40,000 youngsters [24]), we 
had to choose from the above-listed preparations. 
In the course of detailed analysis of advantages and 
disadvantages of these vaccines, we considered several 
factors: safety, efficacy, the duration of immunity after a 
single immunization, availability of efficient production 
technology, and the price of the product. As a result, we 
came to the conclusion that the live ca vaccine is the most 
preferential candidate for development in Kazakhstan. 
The cornerstone of success in the development of the 
first live ca vaccine against equine influenza in Kazakhstan 
was the generation of the vaccine strain. This problem 
was solved in collaboration with the Research Institute 
of Influenza (RII, Saint Petersburg, Russia) where the 
ca master strain A/Hong Kong/1/68/162/35 (H3N2) 
was generated. The new ca strain A/HK/Otar/6:2/2010 
containing two genes coding the surface proteins (HA, 
NA) from the wild type strain A/equine/Otar/764/2007 
(H3N8, American lineage Florida, clade 2), and six genes 
coding the internal proteins (PB2, PB1, PA, NP, M, NS) from 
the master strain was obtained using the classical genetic 
reassortment method. The wild type strain A/equine/ 
Otar/764/2007 (H3N8) was chosen due to the fact that 
it was isolated during the last 2007 influenza outbreak 
in Kazakhstan. According to the data of phylogenetic 
analysis, the HA gene of this virus is highly homologous 
(99.99%) to HA of the A/equine/Richmond/1/2007 
(H3N8) strain, which was recommended by the World 
Organization for Animal Health (Office International des 
Epizooties, OIE) for the production of a vaccine against 
equine influenza in March 2016 [25]. The ca strain 
A/Hong Kong/1/68/162/35 (H3N2) was used already as a 
donor of attenuation for construction of vaccine strains, 
which proved to be not only safe and effective, but also 
showed high reproductive activity in the cultivating 
system. Based on the ca strain A/Hong Kong/1/68/162/35 
(H3N2), new actual vaccine strains could be obtained 
easily in a short time frame. This was confirmed by the 
successful generation of the vaccine strains A/Saint 
Petersburg/HK/2009 (H1N1), A/Astana/HK/2009 (H5N1), 
and A/Perth/HK/2011 (H3N2) [26]. It is noteworthy that 
the closest and the only commercially available analog – 
vaccine Flu Avert® – does not have this advantage. The 
wild strain A/equine/Kentucky/1991 (H3N8) that was 
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used for the generation of this commercial vaccine was 
passaged 49 times in chicken embryos at 26°C to obtain 
the attenuation phenotype. This means that, in order to 
generate the actual vaccine strain, it will be necessary 
to perform similar operations with the new wild type 
EIV that will take at minimum a year [11]. In contrast, 
the generation of the actual vaccine strain based on 
the A/Hong Kong/1/68/162/35 (H3N2) virus takes no 
more than three months by the classic reassortment 
method. As was shown previously, the vaccine strain 
A/HK/Otar/6:2/2010, cultivated in chicken embryos at 
optimal conditions (the infecting dose, temperature, and 
incubation time), steadily grows up to 9.0 log10 EID50/ml 
[27]. This virus keeps the ca and ts phenotypes and 
shows genetic stability over the course of 20 consecutive 
passages in chicken embryos. Furthermore, the complete 
attenuation of this strain was demonstrated in laboratory 
animals (mice and guinеа pigs) [28]. The obtained results 
prove that the ca reassortant strain A/HK/Otar/6:2/2010 
is a good candidate for the live modified ca vaccine 
against the equine influenza. Further trials of this 
vaccine candidate in yearlings and pregnant mares also 
showed its safety. After a single intranasal immunization 
(with 2 x 109.2 EID50), the animals did not reveal any 
symptoms, including fever, during the entire follow-up 
period (21 days). Only an insignificant replication of the 
vaccine virus was observed (100.75-1.0 EID50/ml) in 12.5–
50% of the immunized yearlings and pregnant mares on 
the first and third days post vaccination. The secretory 
IgA antibodies were formed in vaccinated animals on the 
7th day, while the T-cell immune response – on the 14th 
day post vaccination. The vaccinated animals showed 
pronounced clinical (illness severity and duration) and 
virological (virus titer in the nasal swabs on the 1st-14th 
day after the challenge) protection from the homologous 
wild strain A/equine/Otar/764/2007 (H3N8) compared to 
the control group [29]. It is interesting that before the 
challenge the antibodies to EIV of H3 subtype were not 
detected in the blood serum of the vaccinated yearlings 
and pregnant meres by hemagglutination inhibition 
assay (HAI) and ELISA. 
The duration of the protective immune response 
against the equine influenza H3N8 in horses after the first 
and the recurrent immunizations by the live ca vaccine is 
of particular interest. We were the first to demonstrate 
the ability of this vaccine to generate clinical and 
virological protection from the homologous wild type 
virus A/equine/Otar/764/2007 (H3N8) for a period of 
12 months after а single intranasal immunization [30]. 
As was published earlier, the commercial vaccine (Flu 
Avert®, Heska Corporation) generates only a 6-month 
protective immune response in horses after a single 
vaccination [2, 9]. 
It is important to mention that the double intranasal 
vaccination with A/HK/Otar/6:2/2010 (42 days interval) 
can significantly enhance the clinical and virological 
protection from the wild type virus compared to a single 
vaccination. In addition, this vaccine generates sterile 
immunity (the lack of virus in the nasal swabs of animals 
after the challenge) lasting for three months after the 
second immunization [30]. The sterile immunity in horses 
was demonstrated earlier by an immunization scheme 
patented by Intervet International  B.V. (Boxmeer, NL)
[31]. In order to achieve the sterile protective immunity, 
it was necessary to vaccinate horses with the live ca 
vaccine first and then to repeat the immunization with 
an inactivated vaccine against the equine influenza 
virus in 8 weeks. Another example of the generation of 
the sterile protective immunity in horses was reported 
after immunization with a live vector vaccine based on 
the canarypox virus containing the adjuvant Carbopol 
[32]. We report here for the first time that the sterile 
protective immunity against influenza in horses can 
be achieved after double immunization using only 
a live ca vaccine. Besides the sterile immunity, the 
pronounced clinical and virological protection of horses 
against the heterologous wild type virus A/equine/
Sydney/2888-8/2007 (H3N8) was observed 12  months 
after the double, but not single immunization [30]. The 
comparative analysis of our results with the literature 
data [5, 15, 33, 34] demonstrated that in terms of the 
duration of the protective immune response, the live 
attenuated vaccine produced from the reassortant 
ca strain A/HK/Otar/6:2/2010 exceeds all the known 
(inactivated and recombinant) commercial EIV vaccines. 
The obtained results make it possible to assume that 
the developed vaccine has the potential to become an 
excellent alternative for the inactivated and recombinant 
vaccines that are used in Kazakhstan and other countries 
at present. 
According to the OIE recommendations, vaccine 
preparations against equine influenza, in addition to 
being safe and immunogenic, should also enable the 
differentiation of infected from vaccinated animals 
(DIVA strategy) [35]. At present, only live recombinant 
vector vaccines that express the surface influenza virus 
proteins meet these requirements fully [36]. In the case of 
immunization with the traditional inactivated vaccines, 
it is also possible to differentiate the infected from 
vaccinated animals through the detection of antibodies 
to the nonstructural NS1 protein of the influenza virus by 
serological tests [37]. These antibodies are formed only in 
the case of the live virus replication. With respect to the live 
attenuated vaccines against equine influenza, the DIVA 
strategy is impracticable because both the vaccine and 
the wild type viruses induce similar infectious processes 
in animals. However, our serological studies clearly show 
the possibility to differentiate infected from vaccinated 
animals with the live modified ca vaccine strain 
A/HK/Otar/6:2/2010 [30]. The key distinctive feature that 
allows for the differentiation of animals is the absence 
of the antibodies in HAI in the course of 12 months 
after the first and, more importantly, after the second 
immunization of horses with this vaccine. However, 
significant geometric mean titers (GMT) of antibodies 
were detected in HAI on the 28th day after the challenge 
with the homologous (A/equine/Otar/764/2007 H3N8) 
or heterologous (A/equine/Sydney/2888-8/2007 H3N8) 
viruses. The observed GMT ranged from 168±27 to 
672±144 (95% confidence interval) in all the horses 
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immunized once or twice at different time intervals 
(1, 2, 4, 5, 6, 9, or 12 months) after the vaccination. These 
data, presented here for the first time, suggest that the 
developed vaccine enables the differentiation of infected 
from vaccinated animals using such prevalent and 
accessible serological test as HAI. 
The final step in vaccine development was the 
production of the control pilot plant batch of this vaccine 
with consecutive product quality tests (according to 
all the parameters listed in vaccine specification) and 
the verification of the vaccine production technology. 
For this purpose, a vaccine batch of 13,400 ampoules 
(134,000 doses) was produced. According to the results 
of the technological and biological controls, this vaccine 
batch fully complied with the standard specification 
for vaccine preparation in terms of appearance, level of 
foreign impurities, the preasure level within ampules, 
solubility, pH, specific humidity, sterility, infectious 
titer, safety, and immunogenicity. Based on this result, 
the technical documentation package, including the 
specifications for the new vaccine, was prepared and 
approved by the regulatory authorities [38].
Thus, as a result of the integrated studies started from 
the generation of the vaccine strain and finished with the 
production of the pilot vaccine batch, the new, safe, and 
effective modified ca virus vaccine against the EIV was 
developed. This vaccine significantly outperforms the 
other commercial preparations in a number of features. 
In 2016-2017, field studies of this vaccine on the 
horse breeding farms in Kazakhstan are planned. The 
developed vaccine has a high potential to prevent equine 
influenza epidemics. 
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